Clinical Trial: Mirdametinib to Reduce the Size of Large/Giant Congenital Melanocytic Nevi in Children, Adolescents and Young Adults

U.S., Oct. 24 -- ClinicalTrials.gov registry received information related to the study (NCT07891286) titled 'Mirdametinib to Reduce the Size of Large/Giant Congenital Melanocytic Nevi in Children, Adolescents and Young Adults' on Oct. 22.

Brief Summary: Background:

Large and giant congenital melanocytic nevi (LGCMN) are dark birthmarks (moles). They can grow to 8 inches or more across. People with LGCMN have an increased risk of getting skin cancer or problems with the nervous system. Researchers want to find out if a drug approved for a different use (mirdametinib) can shrink the size of LGCMN.

Objective:

To test mirdametinib in people with LGCMN.

Eligibility:

People aged 3 to 40 years with LGCMN.

Design:

Participants will be scree...